

# Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma

## Authors

Jessie Zhao,<sup>1,2</sup> Tiffany Khong,<sup>1,2</sup> Malgorzata Gorniak,<sup>3</sup> Abir Khaled,<sup>4</sup> Zac McDonald,<sup>4</sup> John Reynolds,<sup>1,2</sup> Sridurga Mithraprabhu,<sup>1,2</sup> Nicholas Bingham,<sup>1,2</sup> Suehli Lim,<sup>1,2</sup> Daniel Wong,<sup>1,2</sup> Anna Johnston,<sup>5</sup> Olga Motorna,<sup>6</sup> Nicholas Murphy,<sup>5</sup> Hang Quach,<sup>7</sup> Liqiang Yang<sup>4</sup> and Andrew Spencer<sup>1,2</sup>

<sup>1</sup>Department of Malignant Hematology & Stem Cell Transplantation, The Alfred Hospital, Melbourne, Victoria, Australia; <sup>2</sup>Australian Center for Blood Diseases, Monash University, Melbourne, Victoria, Australia; <sup>3</sup>Alfred Pathology, The Alfred Hospital, Melbourne, Victoria, Australia; <sup>4</sup>Rapid Novor, Kitchener, Ontario, Canada; <sup>5</sup>Department of Hematology, Royal Hobart Hospital, Hobart, Tasmania, Australia; <sup>6</sup>Department of Hematology, Eastern Health, Melbourne, Victoria, Australia and

<sup>7</sup>Department of Hematology, St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia

Correspondence:  
A. SPENCER - [andrew.spencer@monash.edu](mailto:andrew.spencer@monash.edu)

<https://doi.org/10.3324/haematol.2024.285933>

Received: May 28, 2024.

Accepted: October 29, 2024.


Early view: November 7, 2024.

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license



Supplementary Figure 1. **MM19 and MM21 trial schema.** ASCT, autologous stem cell transplantation; DRd, daratumumab-lenalidomide-dexamethasone; ITd, ixazomib-thalidomide-dexamethasone; MM, multiple myeloma; MRD, minimal residual disease; MS, mass spectrometry; NGF, next-generation flow cytometry; PD, progressive disease; PR, partial response; R, lenalidomide; Td, thalidomide-dexamethasone.



Supplementary Figure 2. **Overview of the EasyM assay.** LC-MS/MS, liquid chromatography with tandem mass spectrometry; M-protein, monoclonal protein.

